Patent · US Active

Compositions and methods for modulating Tau expression

US9644207B2 · kind B2 · utility

9Cited by
57References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 14, 2014
Grant dateMay 9, 2017
Priority date
Expiry dateMar 14, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.